KR20150124457A - 위태로운 조직의 산소화 증강 방법 - Google Patents
위태로운 조직의 산소화 증강 방법 Download PDFInfo
- Publication number
- KR20150124457A KR20150124457A KR1020157030550A KR20157030550A KR20150124457A KR 20150124457 A KR20150124457 A KR 20150124457A KR 1020157030550 A KR1020157030550 A KR 1020157030550A KR 20157030550 A KR20157030550 A KR 20157030550A KR 20150124457 A KR20150124457 A KR 20150124457A
- Authority
- KR
- South Korea
- Prior art keywords
- blood
- composition
- transfusion
- copolymer
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 238000006213 oxygenation reaction Methods 0.000 title abstract description 23
- 230000002708 enhancing effect Effects 0.000 title description 3
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 119
- 210000004369 blood Anatomy 0.000 claims abstract description 116
- 239000008280 blood Substances 0.000 claims abstract description 116
- -1 polyoxyethylene Polymers 0.000 claims abstract description 81
- 208000014674 injury Diseases 0.000 claims abstract description 47
- 230000008733 trauma Effects 0.000 claims abstract description 46
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 43
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract description 42
- 208000007502 anemia Diseases 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 230000001154 acute effect Effects 0.000 claims abstract description 15
- 208000010718 Multiple Organ Failure Diseases 0.000 claims abstract description 12
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims abstract description 12
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 11
- 208000034486 Multi-organ failure Diseases 0.000 claims abstract description 11
- 208000007056 sickle cell anemia Diseases 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 206010040070 Septic Shock Diseases 0.000 claims abstract description 9
- 230000036303 septic shock Effects 0.000 claims abstract description 9
- 208000028867 ischemia Diseases 0.000 claims abstract description 8
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims abstract description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 7
- 206010049771 Shock haemorrhagic Diseases 0.000 claims abstract description 7
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 7
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 7
- 208000006011 Stroke Diseases 0.000 claims abstract description 6
- 208000010444 Acidosis Diseases 0.000 claims abstract description 5
- 230000007950 acidosis Effects 0.000 claims abstract description 5
- 208000026545 acidosis disease Diseases 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 52
- 238000003860 storage Methods 0.000 claims description 34
- 229920001577 copolymer Polymers 0.000 claims description 24
- 238000001802 infusion Methods 0.000 claims description 22
- 238000001356 surgical procedure Methods 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 125000001165 hydrophobic group Chemical group 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 206010051895 acute chest syndrome Diseases 0.000 claims description 8
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 7
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 7
- 230000000740 bleeding effect Effects 0.000 claims description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 208000019838 Blood disease Diseases 0.000 claims description 5
- 208000014951 hematologic disease Diseases 0.000 claims description 5
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 5
- 239000013542 high molecular weight contaminant Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000013541 low molecular weight contaminant Substances 0.000 claims description 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 3
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 80
- 229910052760 oxygen Inorganic materials 0.000 abstract description 80
- 239000001301 oxygen Substances 0.000 abstract description 80
- 210000000056 organ Anatomy 0.000 abstract description 33
- 206010040047 Sepsis Diseases 0.000 abstract description 20
- 208000035475 disorder Diseases 0.000 abstract description 16
- 238000002054 transplantation Methods 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 4
- 208000000038 Hypoparathyroidism Diseases 0.000 abstract description 3
- 206010021113 Hypothermia Diseases 0.000 abstract description 3
- 230000002631 hypothermal effect Effects 0.000 abstract description 3
- 201000002818 limb ischemia Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 210000000115 thoracic cavity Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 54
- 230000000287 tissue oxygenation Effects 0.000 description 34
- 230000001965 increasing effect Effects 0.000 description 30
- 108010054147 Hemoglobins Proteins 0.000 description 27
- 102000001554 Hemoglobins Human genes 0.000 description 27
- 230000000694 effects Effects 0.000 description 18
- 230000010412 perfusion Effects 0.000 description 18
- 230000004089 microcirculation Effects 0.000 description 17
- 230000036284 oxygen consumption Effects 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 230000007423 decrease Effects 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 229920001400 block copolymer Polymers 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 230000035939 shock Effects 0.000 description 13
- 208000028399 Critical Illness Diseases 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 10
- 238000004497 NIR spectroscopy Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 206010053159 Organ failure Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000002980 postoperative effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000000004 hemodynamic effect Effects 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 6
- 238000007675 cardiac surgery Methods 0.000 description 6
- 230000002939 deleterious effect Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- GEVPIWPYWJZSPR-UHFFFAOYSA-N tcpo Chemical compound ClC1=CC(Cl)=CC(Cl)=C1OC(=O)C(=O)OC1=C(Cl)C=C(Cl)C=C1Cl GEVPIWPYWJZSPR-UHFFFAOYSA-N 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 5
- 208000003441 Transfusion reaction Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 206010067268 Post procedural infection Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002316 cosmetic surgery Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000000250 revascularization Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000010865 video microscopy Methods 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 206010053648 Vascular occlusion Diseases 0.000 description 3
- 206010069351 acute lung injury Diseases 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000021331 vascular occlusion disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010021137 Hypovolaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010067122 Haemolytic transfusion reaction Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 108010068048 S-nitrosohemoglobin Proteins 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010041649 Splenic injury Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010071090 Transfusion related complication Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002146 exchange transfusion Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000000352 storage cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008343 sublingual microcirculation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41351910P | 2010-11-15 | 2010-11-15 | |
| US61/413,519 | 2010-11-15 | ||
| PCT/US2011/060747 WO2012068079A1 (en) | 2010-11-15 | 2011-11-15 | Methods for enhancing oxygenation of jeopardized tissue |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137015206A Division KR20130097795A (ko) | 2010-11-15 | 2011-11-15 | 위태로운 조직의 산소화 증강 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150124457A true KR20150124457A (ko) | 2015-11-05 |
Family
ID=46084364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157030550A Ceased KR20150124457A (ko) | 2010-11-15 | 2011-11-15 | 위태로운 조직의 산소화 증강 방법 |
| KR1020137015206A Ceased KR20130097795A (ko) | 2010-11-15 | 2011-11-15 | 위태로운 조직의 산소화 증강 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137015206A Ceased KR20130097795A (ko) | 2010-11-15 | 2011-11-15 | 위태로운 조직의 산소화 증강 방법 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20130177524A1 (enExample) |
| EP (1) | EP2640684A4 (enExample) |
| JP (2) | JP5823530B2 (enExample) |
| KR (2) | KR20150124457A (enExample) |
| CN (1) | CN103328427A (enExample) |
| AU (1) | AU2011329088B2 (enExample) |
| BR (1) | BR112013011858A2 (enExample) |
| CA (1) | CA2817542A1 (enExample) |
| CL (1) | CL2013001382A1 (enExample) |
| EA (1) | EA201390720A1 (enExample) |
| IL (1) | IL226285A0 (enExample) |
| MX (1) | MX2013005457A (enExample) |
| NZ (1) | NZ610441A (enExample) |
| PE (1) | PE20140134A1 (enExample) |
| SG (1) | SG190695A1 (enExample) |
| WO (1) | WO2012068079A1 (enExample) |
| ZA (1) | ZA201303416B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103328427A (zh) * | 2010-11-15 | 2013-09-25 | 马斯特治疗公司 | 增强受到危害的组织的氧合的方法 |
| GB201207543D0 (en) * | 2012-05-01 | 2012-06-13 | Haemair Ltd | Treatment of transfusion blood |
| CA2927361A1 (en) * | 2013-10-16 | 2015-04-23 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
| US9403941B2 (en) | 2014-07-07 | 2016-08-02 | Mast Therapeutics, Inc. | Poloxamer composition free of long circulating material and methods for production and uses thereof |
| US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
| WO2016007542A1 (en) | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
| EP3873441A4 (en) | 2018-12-10 | 2022-06-29 | Arshintseva, Elena Valentinovna | A new use of the poloxamer as a pharmacologically active substance |
| EP4401554A4 (en) * | 2021-08-18 | 2025-10-15 | Omniox Inc | H-NOX PROTEINS FOR ORGAN PRESERVATION |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030448A (en) | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
| US5017370A (en) | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
| US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5032394A (en) | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
| US4997644A (en) | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
| US5028599A (en) | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
| US5047236A (en) | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
| US4837014A (en) | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
| US5080894A (en) | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
| US5089260A (en) | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
| US4873083A (en) | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
| US5064643A (en) | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
| US4937070A (en) | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5071649A (en) | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
| US5078995A (en) | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
| US4879109A (en) | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
| US4801452A (en) | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
| US5039520A (en) | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
| US5041288A (en) | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| WO1992016484A1 (en) * | 1991-03-19 | 1992-10-01 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US5605687A (en) | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| US7087369B2 (en) * | 2003-12-17 | 2006-08-08 | The Regents Of The University Of California | Cornea preservation medium |
| EP1804813A4 (en) * | 2004-09-27 | 2011-09-07 | Vical Inc | FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| WO2009023177A1 (en) * | 2007-08-10 | 2009-02-19 | Synthrx, Inc. | Polymer therapy for the treatment of chronic microvascular diseases |
| CN103328427A (zh) * | 2010-11-15 | 2013-09-25 | 马斯特治疗公司 | 增强受到危害的组织的氧合的方法 |
-
2011
- 2011-11-15 CN CN2011800648610A patent/CN103328427A/zh active Pending
- 2011-11-15 WO PCT/US2011/060747 patent/WO2012068079A1/en not_active Ceased
- 2011-11-15 MX MX2013005457A patent/MX2013005457A/es not_active Application Discontinuation
- 2011-11-15 EA EA201390720A patent/EA201390720A1/ru unknown
- 2011-11-15 BR BR112013011858A patent/BR112013011858A2/pt not_active IP Right Cessation
- 2011-11-15 KR KR1020157030550A patent/KR20150124457A/ko not_active Ceased
- 2011-11-15 CA CA2817542A patent/CA2817542A1/en not_active Abandoned
- 2011-11-15 SG SG2013035449A patent/SG190695A1/en unknown
- 2011-11-15 PE PE2013001082A patent/PE20140134A1/es not_active Application Discontinuation
- 2011-11-15 NZ NZ610441A patent/NZ610441A/en unknown
- 2011-11-15 AU AU2011329088A patent/AU2011329088B2/en active Active
- 2011-11-15 JP JP2013538989A patent/JP5823530B2/ja active Active
- 2011-11-15 KR KR1020137015206A patent/KR20130097795A/ko not_active Ceased
- 2011-11-15 EP EP11841387.1A patent/EP2640684A4/en not_active Withdrawn
-
2013
- 2013-03-01 US US13/783,158 patent/US20130177524A1/en not_active Abandoned
- 2013-05-09 IL IL226285A patent/IL226285A0/en unknown
- 2013-05-10 ZA ZA2013/03416A patent/ZA201303416B/en unknown
- 2013-05-15 CL CL2013001382A patent/CL2013001382A1/es unknown
-
2014
- 2014-11-25 US US14/553,913 patent/US20150093368A1/en not_active Abandoned
-
2015
- 2015-10-07 JP JP2015199281A patent/JP2016041714A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013011858A2 (pt) | 2017-03-21 |
| CA2817542A1 (en) | 2012-05-24 |
| CL2013001382A1 (es) | 2013-12-20 |
| JP2014506234A (ja) | 2014-03-13 |
| CN103328427A (zh) | 2013-09-25 |
| PE20140134A1 (es) | 2014-02-14 |
| SG190695A1 (en) | 2013-07-31 |
| AU2011329088A1 (en) | 2013-06-27 |
| EP2640684A1 (en) | 2013-09-25 |
| JP5823530B2 (ja) | 2015-11-25 |
| IL226285A0 (en) | 2013-07-31 |
| AU2011329088B2 (en) | 2016-02-25 |
| EA201390720A1 (ru) | 2013-10-30 |
| EP2640684A4 (en) | 2014-04-30 |
| WO2012068079A1 (en) | 2012-05-24 |
| ZA201303416B (en) | 2017-03-29 |
| US20130177524A1 (en) | 2013-07-11 |
| US20150093368A1 (en) | 2015-04-02 |
| NZ610441A (en) | 2016-02-26 |
| KR20130097795A (ko) | 2013-09-03 |
| JP2016041714A (ja) | 2016-03-31 |
| MX2013005457A (es) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150124457A (ko) | 위태로운 조직의 산소화 증강 방법 | |
| JP7009059B2 (ja) | 酸素化コレステロール硫酸塩（ｏｃｓ）の使用 | |
| JP2014506234A5 (enExample) | ||
| Carson et al. | Anemia and red blood cell transfusion | |
| EP2683374B1 (en) | Use of vanadium compounds for maintaining normaglycemia in a mammal | |
| CA2085475A1 (en) | Hyperosmotic solutions for isonatremic resuscitation | |
| Prough | Crystalloids versus colloids in the perioperative period | |
| Valeri et al. | Red cell 2, 3 DPG, ATP, and creatine levels in preserved red cells and in patients with red cell mass deficits or with cardiopulmonary insufficiency | |
| Fujita et al. | Before-after study of a restricted fluid infusion strategy for management of donor hepatectomy for living-donor liver transplantation | |
| Tsukamoto et al. | Fatal hyperkalemia due to rapid red cell transfusion in a critically ill patient | |
| Kane et al. | Resuscitation of the trauma patient | |
| Tubili | 0.9% saline solution:“physiological” or “unphysiological”? | |
| Yu et al. | SMALL-VOLUME RESUSCITATION FROM TRAUMATIC SHOCK WITH GEKOTON | |
| Schweizer | Anesthesia for Hepatic Lobectomy | |
| Picozzi | Concezione Tommasino* MD | |
| Raisis et al. | Fluid therapy | |
| Ayhan et al. | The effects of non-leukoreduced red blood cell transfusions on microcirculation in mixed surgical patients. | |
| Munoz et al. | 9. Sedation and Analgesia | |
| Shander et al. | Anemia and Blood Conservation in the Critically Ill Patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20151022 Application number text: 1020137015206 Filing date: 20130613 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20151201 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160708 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170201 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20160708 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20151201 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |